Disease modification in OA - will we ever get there?

Affiliations

¹ Department of Clinical Sciences Lund, Orthopaedics, Faculty of Medicine, Lund University, Lund, Sweden. stefan.lohmander@med.lu.se.
² Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.

Comment

L Stefan Lohmander et al. Nat Rev Rheumatol. 2019 Mar.

. 2019 Mar;15(3):133-135.

doi: 10.1038/s41584-019-0174-1.

¹ Department of Clinical Sciences Lund, Orthopaedics, Faculty of Medicine, Lund University, Lund, Sweden. stefan.lohmander@med.lu.se.
² Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.

No abstract available

Comment on

Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs.
Kraus VB, Simon LS, Katz JN, Neogi T, Hunter D, Guermazi A, Karsdal MA. Kraus VB, et al. Osteoarthritis Cartilage. 2019 Apr;27(4):571-579. doi: 10.1016/j.joca.2018.11.002. Epub 2018 Nov 19. Osteoarthritis Cartilage. 2019. PMID: 30465809 Free PMC article. Review.